文献速递胸部肿瘤乳腺癌消化系统肿瘤

新冠疫情期间国际癌症诊断与分期变化:ICBP人群研究

International disruptions to cancer diagnosis and stage at presentation during the COVID-19 pandemic in 2020: an International Cancer Benchmarking Partnership (ICBP) population-based study.
PubMed 文献 · Lancet Oncol · 2026-01-01

BACKGROUND: The COVID-19 pandemic had an impact on cancer services globally. There is a crucial need to understand how the incidence and stage of major cancer types were affected internationally.…

核心结论

  • 新冠疫情对癌症诊断的最大影响发生在2020年早期封锁期间,医疗可及性障碍最大时。

主要发现

  • 前列腺癌缺失24%,女性乳腺癌18%,黑色素瘤18%,卵巢癌4%,肺癌8%。
  • 观察与预测病例缺失百分比:前列腺癌英国54%、爱尔兰36%;乳腺癌英国40%、爱尔兰34%;黑色素瘤英国40%、加拿大35%。

临床怎么用

  • 需关注疫情封锁期间可能漏诊的患者,评估其是否延迟诊断或分期偏晚。

局限性

  • 研究未报告漏诊患者是否后续诊断或分期是否偏晚,需进一步研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The COVID-19 pandemic had an impact on cancer services globally. There is a crucial need to understand how the incidence and stage of major cancer types were affected internationally. We aimed to assess these metrics in seven countries within the International Cancer Benchmarking Partnership. METHODS: This population-based study used data on 2·6 million patients diagnosed with primary cancers of the colon, rectum, lung, prostate, female breast, ovary, and melanoma of the skin, between Jan 1, 2015, and Dec 31, 2020. Data were collected from cancer registries in 18 jurisdictions from seven countries participating in the International Cancer Benchmarking Partnership; Australia, Canada, Denmark, Ireland, New Zealand, Norway, and the UK. The main outcomes of monthly cases and age-standardised incidence rates by site during the pandemic (April 1 to Dec 31, 2020) were compared with predictions for the same year based on pre-pandemic trends (Jan 1, 2015, to Dec 31, 2019). FINDINGS: Between April 1, and Dec 31, 2020, 55 713 (16%) of 347 666 expected cases were predicted to be missing, with the largest deficits seen for prostate cancer (24%), female breast cancer (18%), and melanoma (18%), and the smallest deficits seen for ovarian (4%) and lung cancer (8%). The largest difference between observed and predicted incidence rates for prostate cancer was seen in the UK (164·9 per 100 000 person-years predicted vs 101·4 per 100 000 person-years observed) and the smallest difference seen in Norway (164·1 vs 168·4). Reductions in incidence were greatest from April 1, to July 31, versus from Aug 1, to Dec 31, in 2020. The percentage deficits between observed and predicted cases were 54% (UK) and 36% (Ireland) for prostate cancer, 40% (UK) and 34% (Ireland) for breast cancer, and 40% (UK) and 35% (Canada) for melanoma. INTERPRETATION: The pandemic's greatest impact was during the first few months of societal lockdowns in 2020 when barriers in access to health care were greatest. Further research is needed to understand whether patients with a missed diagnosis were diagnosed at a later date and if they presented at a later stage. FUNDING: Canadian Partnership Against Cancer; Cancer Council Victoria; Cancer Institute New South Wales; Cancer Research UK; Danish Cancer Society; National Cancer Registry Ireland; The Higher Education Authority North South Research Programme, Health Data Research UK; Te Aho o Te Kahu, Cancer Control Agency New Zealand; New Zealand Cancer Society; National Health Service England; Norwegian Cancer Society; Public Health Agency Northern Ireland, on behalf of the Northern Ireland Cancer Registry; The Scottish Government; Western Australia Department of Health; and Wales Cancer Network.

来源:Lancet Oncol,查看原文。版权归原作者所有。

引用

  1. Morgan E, Bardot A, Langselius O, et al. International disruptions to cancer diagnosis and stage at presentation during the COVID-19 pandemic in 2020: an International Cancer Benchmarking Partnership (ICBP) population-based study. Lancet Oncol. 2026. PMID: 42225103. doi:10.1016/S1470-2045(26)00089-6

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。